A long-running English research revealed that young women have an 87 per cent decreased chance of getting cervical cancer due to the human papillomavirus (HPV) if they are vaccinated against the virus in their teens using an earlier GlaxoSmithKline medication called Cervarix.
While in their 20s, the women who had been administered the series of injections of the vaccine when they were between the ages of 12 and 13 years, had an 87 per cent lower chance of having cervical cancer compared to those women who had not been vaccinated and who were checked for the disease.
Researchers revealed in The Lancet medical journal that when the vaccines were administered to women between the ages of 14 and 16 years, the cancer risk reduced by 62 per cent, and it was 34 per cent lower in women immunized between the ages of 16 and 18.
Further, there was a 97 per cent lower chance of a precancerous condition developing because of the disease in women who had been administered the vaccine when they were between the ages 12 and 13 years, the study also concluded.
The findings “should greatly reassure those still hesitant about the benefits of HPV vaccination,” the researchers said.
Funded by the Cancer Research UK, the research examined registry data from January 2006 to June 2019 on women between the ages of 20 and 64 who had been checked for cervical cancer, including those who had the Cervarix vaccination when it became available in 2008.
Data indicated that around 28,000 cases of cervical cancer and 300,000 cases of a precancerous disease known as cervical intraepithelial neoplasia (CIN3) were diagnosed in England over a nearly 13-year period.
Vaccinated young women had approximately 450 fewer incidents of cervical cancer and 17,200 fewer instances of CIN3 than the women of the same age who had not been vaccinated.
“We hope that these new results encourage uptake as the success of the vaccination program relies not only on the efficacy of the vaccine but also the proportion of the population vaccinated,” said coauthor Kate Soldan of the UK Health Security Agency.
Protection against two types of HPV strains, which is responsible for around 70 per cent to 80 per cent of all cervical malignancies, is provided by the FSK-developed vaccine – Cervarix.
In England, the quadrivalent vaccination Gardasil developed by Merck & Co., which ic claimed to provide protection against four HPV strains associated with cervical and head and neck cancers, has been used instead of Cervarix since September 2012.
Poor demand for the vaccine has also prompted GSK to discontinue sales of Cervarix in the United States, with Gardasil being the dominant player in the most profitable market of the world.
Cervical cancer in young women is uncommon. To adequately analyze the immunizations’ impact, women must be followed up on as they become older. (Adapted from Latestly.com)